Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma

This study is testing whether a prolonged course of a combination of drugs — naxitamab, irinotecan, and temozolomide — is safe and feasible for children and young adults with neuroblastoma (a childhood cancer) that has come back or stopped responding to treatment. **You may be eligible if:** - You have been diagnosed with high-risk neuroblastoma (confirmed by biopsy at original diagnosis) - Your cancer has relapsed (come back) after completing standard treatment, or it progressed during standard treatment - You are in adequate physical health to receive treatment - Certain lab values (blood, kidney, liver, heart function) are within acceptable ranges **You may NOT be eligible if:** - You have active, uncontrolled infection - You have significant organ damage (heart, kidney, liver) - You are pregnant or breastfeeding - You have a history of severe allergic reaction to any of the study drugs - You have progressing cancer that has spread to the brain Talk to your doctor to see if this trial is right for you.